Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors - PubMed
5 hours ago
- #colorectal cancer
- #Phase I trial
- #c-Met antibody-drug conjugate
- Phase I study of Telisotuzumab Adizutecan (ABBV-400), a novel c-Met antibody-drug conjugate, in patients with late-line colorectal cancer and advanced solid tumors.
- The study aims to evaluate the safety, tolerability, and efficacy of the drug in this patient population.
- Published online ahead of print in the Journal of Clinical Oncology (JCO) in 2026.